Andrea Nicole Weber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Nicole Weber has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Stephan Arndt
Department of Psychiatry, University of Iowa Health Care , Iowa City, IA 52242, United States of America
9 shared publicationsBenjamin Miskle
Department of Psychiatry, University of Iowa, Iowa City, IA, USA
7 shared publications- Nicholas L. Bormann
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
7 shared publications Alison Lynch
Department of Psychiatry University of Iowa Iowa City Iowa USA
4 shared publicationsAlison C. Lynch
Department of Psychiatry University of Iowa Iowa City Iowa USA
2 shared publications- Jess G. Fiedorowicz
Ottawa Hospital Research Institute Clinical Epidemiology Program, Ottawa, Ontario, Canada
2 shared publications
Latest Publications
- Open Access
- 16 September 2025
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 60 (6)
Integrated approaches to reduce alcohol use in people with liver disease: a scoping review and quantitative analysis
Aims: Alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) are interconnected and highly prevalent. Integrating substance use disorder (SUD) treatment into medical clinics may increase access to specialized care and improve liver-related outcomes. Methods: A scoping review and quantitative analysis were completed on published literature before 4 September 2024. Included articles described SUD treatment integrated in medical settings for adults with liver disease and alcohol use. Specific focus in the analysis was placed on integrations that utilized telehealth formats, facilitated access to medications for AUD (MAUD), and intervened in liver transplant populations. Results: Twenty-three full-length manuscripts and 10 conference abstracts met the inclusion criteria. Fourteen articles discussed MAUD access in ALD populations. Nine utilized telehealth interventions, and 12 focused on pre- and post-liver transplant populations considered high-risk for returning to alcohol use. Nine full-length manuscripts were included in a quantitative analysis, which showed a 9.7% risk difference (95% CI: 5.9–13.4) in any alcohol use, favoring integrated care over treatment as usual. Conclusions: Integrated care for AUD and concurrent ALD populations can effectively reduce returns to alcohol use and be successfully integrated in a medical setting. The core ingredient of such interventions was the inclusion of an addiction medicine specialist into a medical setting, rather than an outside referral. Strategic telehealth utilization can further reduce geographic and specialty-specific barriers to SUD care in medically ill populations. More consensus is needed on key components, processes, and optimal outcomes for such integrated programs for people with concurrent liver disease and AUD.
- 16 September 2025
- Published by Oxford University Press (OUP) in Alcohol and Alcoholism
- Vol. 60 (6)
Open AccessIntegrated approaches to reduce alcohol use in people with liver disease: a scoping review and quantitative analysis
Aims: Alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) are interconnected and highly prevalent. Integrating substance use disorder (SUD) treatment into medical clinics may increase access to specialized care and improve liver-related outcomes. Methods: A scoping review and quantitative analysis were completed on published literature before 4 September 2024. Included articles described SUD treatment integrated in medical settings for adults with liver disease and alcohol use. Specific focus in the analysis was placed on integrations that utilized telehealth formats, facilitated access to medications for AUD (MAUD), and intervened in liver transplant populations. Results: Twenty-three full-length manuscripts and 10 conference abstracts met the inclusion criteria. Fourteen articles discussed MAUD access in ALD populations. Nine utilized telehealth interventions, and 12 focused on pre- and post-liver transplant populations considered high-risk for returning to alcohol use. Nine full-length manuscripts were included in a quantitative analysis, which showed a 9.7% risk difference (95% CI: 5.9–13.4) in any alcohol use, favoring integrated care over treatment as usual. Conclusions: Integrated care for AUD and concurrent ALD populations can effectively reduce returns to alcohol use and be successfully integrated in a medical setting. The core ingredient of such interventions was the inclusion of an addiction medicine specialist into a medical setting, rather than an outside referral. Strategic telehealth utilization can further reduce geographic and specialty-specific barriers to SUD care in medically ill populations. More consensus is needed on key components, processes, and optimal outcomes for such integrated programs for people with concurrent liver disease and AUD.
- 30 May 2025
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 49 (6) , 1286-1296
Positive changes in employment status are associated with reduced alcohol use frequency at discharge from outpatient specialty treatment
Background: Workforce engagement can provide structure, income, feelings of accomplishment, and personal contacts, growing an individual's recovery capital (RC). Employed individuals are also more likely to complete addiction treatment. We sought to investigate whether changes in employment status from alcohol treatment admission to discharge correlated with changes in alcohol use frequency over those time points.Methods: The Treatment Episode Dataset—Discharges (2017–2021) provided the data. Employment status (full‐time, part‐time, unemployed, and not in labor force) and alcohol use frequency (daily use, some use, and no use in past month) were assessed at treatment admission and discharge. Changes in alcohol use frequency during treatment were recorded as Reduction or No reduction. Logistic regression using reduced alcohol use frequency as the dependent variable included employment status at admission and discharge separately. A second analysis included employment status at both admission and discharge and their interaction term. An adjusted model included all covariates (race, ethnicity, age, education, and referral source), with its results being used to derive the marginal probabilities of reduced alcohol use frequency.Results: There were 856,085 alcohol treatment admissions over the 5 years, with 221,724 (25.9%) first admissions. Transitioning from not in the labor force or unemployed to full‐time saw the largest percentage of encounters decreasing alcohol use frequency: 71.9% (95% CI: 70.0–73.7) and 69.3% (95% CI: 68.1–70.5), respectively. Those remaining unemployed had the lowest reduction at 26.7% (95% CI: 26.3–27.1), with a sample reduction of 42.7% (95% CI: 42.5–42.9) overall. Far more people (60.4%) completed treatment within the Reduction group than in the No reduction group (30.2%).Conclusions: Findings suggest that improving employment status may be relevant for reducing alcohol use frequency. This aligns with past work showing overall improved health outcomes with lower unemployment levels. Incorporating vocational training and workforce engagement activities into outpatient treatment may help augment traditional approaches to improve an individual's RC.
- 30 May 2025
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 49 (6) , 1286-1296
Positive changes in employment status are associated with reduced alcohol use frequency at discharge from outpatient specialty treatment
Background: Workforce engagement can provide structure, income, feelings of accomplishment, and personal contacts, growing an individual's recovery capital (RC). Employed individuals are also more likely to complete addiction treatment. We sought to investigate whether changes in employment status from alcohol treatment admission to discharge correlated with changes in alcohol use frequency over those time points.Methods: The Treatment Episode Dataset—Discharges (2017–2021) provided the data. Employment status (full‐time, part‐time, unemployed, and not in labor force) and alcohol use frequency (daily use, some use, and no use in past month) were assessed at treatment admission and discharge. Changes in alcohol use frequency during treatment were recorded as Reduction or No reduction. Logistic regression using reduced alcohol use frequency as the dependent variable included employment status at admission and discharge separately. A second analysis included employment status at both admission and discharge and their interaction term. An adjusted model included all covariates (race, ethnicity, age, education, and referral source), with its results being used to derive the marginal probabilities of reduced alcohol use frequency.Results: There were 856,085 alcohol treatment admissions over the 5 years, with 221,724 (25.9%) first admissions. Transitioning from not in the labor force or unemployed to full‐time saw the largest percentage of encounters decreasing alcohol use frequency: 71.9% (95% CI: 70.0–73.7) and 69.3% (95% CI: 68.1–70.5), respectively. Those remaining unemployed had the lowest reduction at 26.7% (95% CI: 26.3–27.1), with a sample reduction of 42.7% (95% CI: 42.5–42.9) overall. Far more people (60.4%) completed treatment within the Reduction group than in the No reduction group (30.2%).Conclusions: Findings suggest that improving employment status may be relevant for reducing alcohol use frequency. This aligns with past work showing overall improved health outcomes with lower unemployment levels. Incorporating vocational training and workforce engagement activities into outpatient treatment may help augment traditional approaches to improve an individual's RC.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 16, 119-128
Patient Perspectives on a Rapid Access, Walk-in, Medication for Addiction Treatment Clinic
Purpose: Rapid access addiction medicine (RAAM) walk-in clinics offer low-barrier, prompt treatment for substance use disorders (SUDs). These models differ from bridge clinics, which primarily address the barriers of transitioning between inpatient and outpatient SUD treatment settings. Previous RAAM models have been shown to be effective in urban areas. Through patient interviews, this qualitative study sought to describe the unique challenges and successes of a RAAM clinic that serves a primarily rural area. Patients and Methods: Adult patients with a SUD who utilized a medication for addiction treatment (MAT) walk-in clinic participated in semi-structured, recorded interviews. Participants were asked about facilitators and barriers to attaining treatment, as well as their perspectives/experiences and unmet wants/needs. Interviewee responses were transcribed, qualitatively coded, and analyzed for prominent trends. Results: Twelve patients participated. Stigma, lack of rural treatment options, and accessibility concerns were identified as general barriers to receiving SUD care. MAT walk-in clinic specific barriers included distance to clinic, clinic hours, and transportation. Patients identified the clinic’s walk-in structure as a primary facilitator of receiving quality SUD care and felt the clinic offered a non-judgmental and accessible environment, differing positively from past treatments. Unmet wants and needs that patients identified included more extensive social services and communication after leaving the clinic. Conclusion: This MAT walk-in clinic is the only RAAM-style clinic offering same-day dual-diagnosis medication management in the state of Iowa. The walk-in structure was a key facilitator for patients accessing initial care. Expanding RAAM models in rural areas and incorporating telehealth may help address proximity barriers reported by patients.
- 1 May 2025
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 16, 119-128
Open AccessPatient Perspectives on a Rapid Access, Walk-in, Medication for Addiction Treatment Clinic
Purpose: Rapid access addiction medicine (RAAM) walk-in clinics offer low-barrier, prompt treatment for substance use disorders (SUDs). These models differ from bridge clinics, which primarily address the barriers of transitioning between inpatient and outpatient SUD treatment settings. Previous RAAM models have been shown to be effective in urban areas. Through patient interviews, this qualitative study sought to describe the unique challenges and successes of a RAAM clinic that serves a primarily rural area. Patients and Methods: Adult patients with a SUD who utilized a medication for addiction treatment (MAT) walk-in clinic participated in semi-structured, recorded interviews. Participants were asked about facilitators and barriers to attaining treatment, as well as their perspectives/experiences and unmet wants/needs. Interviewee responses were transcribed, qualitatively coded, and analyzed for prominent trends. Results: Twelve patients participated. Stigma, lack of rural treatment options, and accessibility concerns were identified as general barriers to receiving SUD care. MAT walk-in clinic specific barriers included distance to clinic, clinic hours, and transportation. Patients identified the clinic’s walk-in structure as a primary facilitator of receiving quality SUD care and felt the clinic offered a non-judgmental and accessible environment, differing positively from past treatments. Unmet wants and needs that patients identified included more extensive social services and communication after leaving the clinic. Conclusion: This MAT walk-in clinic is the only RAAM-style clinic offering same-day dual-diagnosis medication management in the state of Iowa. The walk-in structure was a key facilitator for patients accessing initial care. Expanding RAAM models in rural areas and incorporating telehealth may help address proximity barriers reported by patients.
- 3 August 2024
- Published by Wiley in The American Journal on Addictions
- Vol. 34 (1) , 60-68
State inequities: Gaps in planned treatment for criminal legal referrals with opioid use disorder across two decades of US treatment admissions
Background and Objectives: Criminal‐legal (CL) referrals to addiction treatment have historically had low utilization of medications for opioid use disorder (MOUD). While state differences have been reported, an in‐depth longitudinal analysis of state‐by‐state differences is lacking.Methods: The Substance Abuse and Mental Health Services Administration Treatment Episode Dataset‐Admissions 2000–2020 provided data for individuals entering their initial treatment with an opioid as their primary substance. Outcome was planned use of MOUD, assessing odds ratio (OR) of CL referrals relative to non‐CL referrals cumulatively over the 21‐year period and as incremental change (change in relative disparity) using effect sizes, stratified by each state.Results: 2,187,447 cases met the criteria. Planned MOUD occurred in 37.7% of non‐CL clients versus 6.5% of CL clients (OR = 0.11, 95% confidence interval = 0.11–0.12). For all clients, planned MOUD increased from 2000 (33.9%) to 2020 (44.8%). This increase was blunted within CL clients, increasing from 2000 (6.4%) to 2020 (13.3%). Rhode Island saw the greatest improvements in equity.Discussion and Conclusions: While rates of planned MOUD increased over the 21 years, a significant disparity persisted among CL clients in most states. As opioid use disorders and opioid‐related overdoses are more prevalent among those involved with the CL system, improving this has high impact.Scientific Significance: Provides the most comprehensive analysis of state‐by‐state inequities in MOUD access for CL relative to non‐CL referrals over a 21‐year period through use of a national data set. Positive outliers are used as case examples for others to follow in pursuit of more equitable care.
- 3 August 2024
- Published by Wiley in The American Journal on Addictions
- Vol. 34 (1) , 60-68
State inequities: Gaps in planned treatment for criminal legal referrals with opioid use disorder across two decades of US treatment admissions
Background and Objectives: Criminal‐legal (CL) referrals to addiction treatment have historically had low utilization of medications for opioid use disorder (MOUD). While state differences have been reported, an in‐depth longitudinal analysis of state‐by‐state differences is lacking.Methods: The Substance Abuse and Mental Health Services Administration Treatment Episode Dataset‐Admissions 2000–2020 provided data for individuals entering their initial treatment with an opioid as their primary substance. Outcome was planned use of MOUD, assessing odds ratio (OR) of CL referrals relative to non‐CL referrals cumulatively over the 21‐year period and as incremental change (change in relative disparity) using effect sizes, stratified by each state.Results: 2,187,447 cases met the criteria. Planned MOUD occurred in 37.7% of non‐CL clients versus 6.5% of CL clients (OR = 0.11, 95% confidence interval = 0.11–0.12). For all clients, planned MOUD increased from 2000 (33.9%) to 2020 (44.8%). This increase was blunted within CL clients, increasing from 2000 (6.4%) to 2020 (13.3%). Rhode Island saw the greatest improvements in equity.Discussion and Conclusions: While rates of planned MOUD increased over the 21 years, a significant disparity persisted among CL clients in most states. As opioid use disorders and opioid‐related overdoses are more prevalent among those involved with the CL system, improving this has high impact.Scientific Significance: Provides the most comprehensive analysis of state‐by‐state inequities in MOUD access for CL relative to non‐CL referrals over a 21‐year period through use of a national data set. Positive outliers are used as case examples for others to follow in pursuit of more equitable care.
- Open Access
- 1 April 2024
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 15, 59-71
Managing Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review
Illicitly manufactured fentanyl (IMF) is a significant contributor to the increasing rates of overdose-related deaths. Its high potency and lipophilicity can complicate opioid withdrawal syndromes (OWS) and the subsequent management of opioid use disorder (OUD). This scoping review aimed to collate the current OWS management of study populations seeking treatment for OWS and/or OUD directly from an unregulated opioid supply, such as IMF. Therefore, the focus was on therapeutic interventions published between January 2010 and November 2023, overlapping with the period of increasing IMF exposure. A health science librarian conducted a systematic search on November 13, 2023. A total of 426 studies were screened, and 173 studies were reviewed at the full-text level. Forty-nine studies met the inclusion criteria. Buprenorphine and naltrexone were included in most studies with the goal of transitioning to a long-acting injectable version. Various augmenting agents were tested (buspirone, memantine, suvorexant, gabapentin, and pregabalin); however, the liberal use of adjunctive medication and shortened timelines to initiation had the most consistently positive results. Outside of FDA-approved medications for OUD, lofexidine, gabapentin, and suvorexant have limited evidence for augmenting opioid agonist initiation. Trials often have low retention rates, particularly when opioid agonist washout is required. Neurostimulation strategies were promising; however, they were developed and studied early. Precipitated withdrawal is a concern; however, the rates were low and adequately mitigated or managed with low- or high-dose buprenorphine induction. Maintenance treatment continues to be superior to detoxification without continued management. Shorter induction protocols allow patients to initiate evidence-based treatment more quickly, reducing the use of illicit or non-prescribed substances.
- 1 April 2024
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 15, 59-71
Open AccessManaging Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review
Illicitly manufactured fentanyl (IMF) is a significant contributor to the increasing rates of overdose-related deaths. Its high potency and lipophilicity can complicate opioid withdrawal syndromes (OWS) and the subsequent management of opioid use disorder (OUD). This scoping review aimed to collate the current OWS management of study populations seeking treatment for OWS and/or OUD directly from an unregulated opioid supply, such as IMF. Therefore, the focus was on therapeutic interventions published between January 2010 and November 2023, overlapping with the period of increasing IMF exposure. A health science librarian conducted a systematic search on November 13, 2023. A total of 426 studies were screened, and 173 studies were reviewed at the full-text level. Forty-nine studies met the inclusion criteria. Buprenorphine and naltrexone were included in most studies with the goal of transitioning to a long-acting injectable version. Various augmenting agents were tested (buspirone, memantine, suvorexant, gabapentin, and pregabalin); however, the liberal use of adjunctive medication and shortened timelines to initiation had the most consistently positive results. Outside of FDA-approved medications for OUD, lofexidine, gabapentin, and suvorexant have limited evidence for augmenting opioid agonist initiation. Trials often have low retention rates, particularly when opioid agonist washout is required. Neurostimulation strategies were promising; however, they were developed and studied early. Precipitated withdrawal is a concern; however, the rates were low and adequately mitigated or managed with low- or high-dose buprenorphine induction. Maintenance treatment continues to be superior to detoxification without continued management. Shorter induction protocols allow patients to initiate evidence-based treatment more quickly, reducing the use of illicit or non-prescribed substances.
- 11 December 2023
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 18 (2) , 185-187
Mortality in Treatment-seeking Older Adults Receiving Medications for Opioid Use Disorder
Objectives: Older adults (OAs; age 55+ years) are increasingly seeking specialty treatment of opioid use disorder. Previous analyses of the Treatment Episode Data Set—Discharges (TEDS-D) database have reported higher rates of in-treatment mortality for those receiving medications for opioid use disorder (MOUD). We evaluate current trends in mortality for treatment-seeking OAs. Methods: Using the 2020 TEDS-D, logistic regression predicted in-treatment mortality for OAs from planned MOUD, service level, and interaction terms. Results: Of the 26,993 OA treatment discharges, 679 people were discharged due to death (2.52%). OAs with MOUD (3.65%, 95% confidence interval [CI], 3.37%–3.95%) were significantly more likely to discharge due to death than those without MOUD (0.82%; 95% CI, 0.66%–1.01%). Most records were for nonintensive outpatient (83.7%; n = 22,588), which had the highest mortality (2.89%; 95% CI, 2.68%–3.11%); intensive services (n = 4405) had a mortality rate of 0.61% (95% CI, 0.42%–0.89%). Among OAs, planned MOUD with nonintensive outpatient services had a mortality rate of 4.17% (95% CI, 3.56%–4.9%). Conclusions: This TEDS-D analysis extends previous literature highlighting a significant interaction between planned MOUD and service intensity on in-treatment mortality for OAs. Additional research is needed to address the causal mechanisms behind these interactions and inform the delivery of safe effective care in the growing OA population.
- 11 December 2023
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 18 (2) , 185-187
Mortality in Treatment-seeking Older Adults Receiving Medications for Opioid Use Disorder
Objectives: Older adults (OAs; age 55+ years) are increasingly seeking specialty treatment of opioid use disorder. Previous analyses of the Treatment Episode Data Set—Discharges (TEDS-D) database have reported higher rates of in-treatment mortality for those receiving medications for opioid use disorder (MOUD). We evaluate current trends in mortality for treatment-seeking OAs. Methods: Using the 2020 TEDS-D, logistic regression predicted in-treatment mortality for OAs from planned MOUD, service level, and interaction terms. Results: Of the 26,993 OA treatment discharges, 679 people were discharged due to death (2.52%). OAs with MOUD (3.65%, 95% confidence interval [CI], 3.37%–3.95%) were significantly more likely to discharge due to death than those without MOUD (0.82%; 95% CI, 0.66%–1.01%). Most records were for nonintensive outpatient (83.7%; n = 22,588), which had the highest mortality (2.89%; 95% CI, 2.68%–3.11%); intensive services (n = 4405) had a mortality rate of 0.61% (95% CI, 0.42%–0.89%). Among OAs, planned MOUD with nonintensive outpatient services had a mortality rate of 4.17% (95% CI, 3.56%–4.9%). Conclusions: This TEDS-D analysis extends previous literature highlighting a significant interaction between planned MOUD and service intensity on in-treatment mortality for OAs. Additional research is needed to address the causal mechanisms behind these interactions and inform the delivery of safe effective care in the growing OA population.
- Open Access
- 10 November 2023
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 9, 100204
Evidence of telescoping in females across two decades of US treatment admissions for injection drug use: 2000–2020
- 10 November 2023
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 9, 100204
Open AccessEvidence of telescoping in females across two decades of US treatment admissions for injection drug use: 2000–2020
- Open Access
- 1 October 2023
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 14, 113-118
Recovery Capital Gains May Precede Craving Reduction in Opioid Use Disorder
Purpose: Cravings for drugs and alcohol have been significantly associated with worse treatment outcomes. We investigated if improvements in recovery capital (RC) (eg, a measure of social capital/network, financial resources, education, and cultural factors) over time were associated with decreased reported cravings. Patients and Methods: The original cohort consisted of 133 participants (63 females) with opioid use disorder seeking outpatient treatment, who completed the Assessment of Recovery Capital (ARC) (range 0 to 50) and the Brief Addiction Monitor (BAM) thrice over the 6-month study. Intervention was medication and case management. Analysis included one-way mixed models testing change over time for ARC total scores and single question craving rating (5-point Likert scale). Cross-lagged panel estimates used structural equation models with variables z-scored, allowing for path coefficient evaluation as standard deviations (sd). Results: Total ARC significantly increased over the study (χ 2 = 33.77, df = 2, p < 0.0001), with baseline of 36.6 (n = 114, sd = 11.1) and 6-month of 41.2 (n = 107, sd = 9.5). Craving also changed significantly (χ 2 = 8.51, df = 2, p < 0.015), with baseline of 1.1 (n = 101, sd = 1.2) and 6-month of 0.9 (n = 107, sd = 1.1). The cross-lag from baseline RC to 3-month craving was significant (β = − 0.28, SE = 0.11, z = − 2.53, p < 0.011). The converse was not true; baseline craving did not affect later RC. Results were similarly significant when comparing 3-month to 6-month. The majority of sample was on buprenorphine. Conclusion: As RC improves, the reported cravings at both 3- and 6-month study time points are significantly reduced. When evaluated inversely, there was not a significant association with baseline cravings and follow-up RC. Significant path coefficients provide an estimation of a directional effect from increased RC towards craving reduction.
- 1 October 2023
- Published by Taylor & Francis in Substance Abuse and Rehabilitation
- Vol. ume 14, 113-118
Open AccessRecovery Capital Gains May Precede Craving Reduction in Opioid Use Disorder
Purpose: Cravings for drugs and alcohol have been significantly associated with worse treatment outcomes. We investigated if improvements in recovery capital (RC) (eg, a measure of social capital/network, financial resources, education, and cultural factors) over time were associated with decreased reported cravings. Patients and Methods: The original cohort consisted of 133 participants (63 females) with opioid use disorder seeking outpatient treatment, who completed the Assessment of Recovery Capital (ARC) (range 0 to 50) and the Brief Addiction Monitor (BAM) thrice over the 6-month study. Intervention was medication and case management. Analysis included one-way mixed models testing change over time for ARC total scores and single question craving rating (5-point Likert scale). Cross-lagged panel estimates used structural equation models with variables z-scored, allowing for path coefficient evaluation as standard deviations (sd). Results: Total ARC significantly increased over the study (χ 2 = 33.77, df = 2, p < 0.0001), with baseline of 36.6 (n = 114, sd = 11.1) and 6-month of 41.2 (n = 107, sd = 9.5). Craving also changed significantly (χ 2 = 8.51, df = 2, p < 0.015), with baseline of 1.1 (n = 101, sd = 1.2) and 6-month of 0.9 (n = 107, sd = 1.1). The cross-lag from baseline RC to 3-month craving was significant (β = − 0.28, SE = 0.11, z = − 2.53, p < 0.011). The converse was not true; baseline craving did not affect later RC. Results were similarly significant when comparing 3-month to 6-month. The majority of sample was on buprenorphine. Conclusion: As RC improves, the reported cravings at both 3- and 6-month study time points are significantly reduced. When evaluated inversely, there was not a significant association with baseline cravings and follow-up RC. Significant path coefficients provide an estimation of a directional effect from increased RC towards craving reduction.
- Open Access
- 25 July 2023
- Published by Wiley in The Journal of Rural Health
- Vol. 40 (1) , 192-194
Integrated care models for co‐occurring alcohol use disorders and alcohol‐associated liver disease in rural communities: Telehealth considerations and opportunities
Alcohol use disorders (AUD) and alcohol-associated liver disease (ALD) have growing impacts on public health, yet many do not receive evidence-based care. People with co-occurring AUD and ALD, especially those in rural communities with less access to specialty care, are most in need of novel integrated care models. The use of telehealth to facilitate co-location within an integrated care model may help to improve access to AUD and ALD care while reducing barriers and improving recovery outcomes for both the substance use disorder and liver disease.
- 25 July 2023
- Published by Wiley in The Journal of Rural Health
- Vol. 40 (1) , 192-194
Open AccessIntegrated care models for co‐occurring alcohol use disorders and alcohol‐associated liver disease in rural communities: Telehealth considerations and opportunities
Alcohol use disorders (AUD) and alcohol-associated liver disease (ALD) have growing impacts on public health, yet many do not receive evidence-based care. People with co-occurring AUD and ALD, especially those in rural communities with less access to specialty care, are most in need of novel integrated care models. The use of telehealth to facilitate co-location within an integrated care model may help to improve access to AUD and ALD care while reducing barriers and improving recovery outcomes for both the substance use disorder and liver disease.
- Open Access
- 2 May 2023
- Published by Wiley in The American Journal on Addictions
- Vol. 32 (6) , 547-553
Improvements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment‐seeking cohort
Background and Objectives: Comorbid substance use can negatively impact multiple aspects of treatment for patients with an opioid use disorder (OUD). We investigated if treatment for OUD led to improvements in patients' recovery capital (RC) overtime, and whether there were associated changes in co‐occurring alcohol use.Methods: Participants (n = 133) were patients with OUD seeking outpatient treatment, who completed the Assessment of Recovery Capital (ARC) and reported drinking days per 30‐day period thrice over the 6‐month study. No specific treatments targeting alcohol were used. Two different models were employed to assess changes in total ARC score and adjusted odds ratio (aOR) for past 30‐day abstinence.Results: Baseline mean ARC scores were 36.6 and significantly increased to mean score of 41.2 at study end. Ninety‐one participants (68.4%) reported no alcohol use at baseline, and 97 (78.9%) reported no use in the previous 30 days at study endpoint. For each increase in ARC, there was an aOR 1.07 (confidence interval [CI]: 1.02–1.13) for past 30‐day abstinence. Considering ARC standard deviation of 10.33 over all measurements, this equates to an aOR of 2.10 (CI: 1.22–3.62) for past 30‐day abstinence.Discussion and Conclusions: We saw significantly increased aOR for past 30‐day abstinence as RC improved in an OUD treatment‐seeking population. This difference was not caused by differences in ARC between study completers and noncompleters.Scientific Significance: Showcases how RC growth may be protective of past 30‐day alcohol use in an OUD cohort and adds specific aOR for abstinence per ARC increase.
- 2 May 2023
- Published by Wiley in The American Journal on Addictions
- Vol. 32 (6) , 547-553
Open AccessImprovements in recovery capital are associated with decreased alcohol use in a primary opioid use disorder treatment‐seeking cohort
Background and Objectives: Comorbid substance use can negatively impact multiple aspects of treatment for patients with an opioid use disorder (OUD). We investigated if treatment for OUD led to improvements in patients' recovery capital (RC) overtime, and whether there were associated changes in co‐occurring alcohol use.Methods: Participants (n = 133) were patients with OUD seeking outpatient treatment, who completed the Assessment of Recovery Capital (ARC) and reported drinking days per 30‐day period thrice over the 6‐month study. No specific treatments targeting alcohol were used. Two different models were employed to assess changes in total ARC score and adjusted odds ratio (aOR) for past 30‐day abstinence.Results: Baseline mean ARC scores were 36.6 and significantly increased to mean score of 41.2 at study end. Ninety‐one participants (68.4%) reported no alcohol use at baseline, and 97 (78.9%) reported no use in the previous 30 days at study endpoint. For each increase in ARC, there was an aOR 1.07 (confidence interval [CI]: 1.02–1.13) for past 30‐day abstinence. Considering ARC standard deviation of 10.33 over all measurements, this equates to an aOR of 2.10 (CI: 1.22–3.62) for past 30‐day abstinence.Discussion and Conclusions: We saw significantly increased aOR for past 30‐day abstinence as RC improved in an OUD treatment‐seeking population. This difference was not caused by differences in ARC between study completers and noncompleters.Scientific Significance: Showcases how RC growth may be protective of past 30‐day alcohol use in an OUD cohort and adds specific aOR for abstinence per ARC increase.